Readystate Asset Management LP Increases Stock Position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)

Readystate Asset Management LP grew its position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 129.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 481,241 shares of the company's stock after purchasing an additional 271,899 shares during the period. Readystate Asset Management LP owned about 0.84% of Structure Therapeutics worth $8,330,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. GF Fund Management CO. LTD. bought a new position in shares of Structure Therapeutics in the fourth quarter valued at approximately $34,000. Virtus ETF Advisers LLC boosted its position in shares of Structure Therapeutics by 25.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock valued at $61,000 after acquiring an additional 455 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of Structure Therapeutics by 673.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,076 shares of the company's stock valued at $111,000 after acquiring an additional 3,549 shares during the period. Headlands Technologies LLC purchased a new stake in Structure Therapeutics in the fourth quarter valued at approximately $113,000. Finally, GAMMA Investing LLC raised its stake in Structure Therapeutics by 663.8% in the first quarter. GAMMA Investing LLC now owns 8,776 shares of the company's stock valued at $152,000 after purchasing an additional 7,627 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

Structure Therapeutics Stock Down 0.3%

GPCR stock traded down $0.06 on Tuesday, reaching $18.07. 297,739 shares of the company's stock were exchanged, compared to its average volume of 817,663. The firm has a market cap of $1.04 billion, a PE ratio of -20.78 and a beta of -1.87. Structure Therapeutics Inc. Sponsored ADR has a twelve month low of $13.22 and a twelve month high of $45.37. The stock has a fifty day moving average of $21.73 and a 200-day moving average of $22.76.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.03). On average, equities research analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Citigroup assumed coverage on shares of Structure Therapeutics in a research note on Friday, May 2nd. They issued a "buy" rating and a $60.00 target price on the stock. HC Wainwright decreased their target price on shares of Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a research note on Monday, May 12th. Cantor Fitzgerald reissued an "overweight" rating and set a $65.00 price objective on shares of Structure Therapeutics in a research report on Monday, June 23rd. Finally, JMP Securities reissued a "market outperform" rating and set a $89.00 price objective on shares of Structure Therapeutics in a research report on Monday, June 23rd. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $76.17.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

Want to see what other hedge funds are holding GPCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.